Research and Markets has announced the addition of the "N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 220.127.116.11) - Pipeline Review, H2 2016" report to their offering.
N Sulphoglucosamine Sulphohydrolase pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.
N Sulphoglucosamine Sulphohydrolase N-sulphoglucosamine sulphohydrolase is an enzyme encoded by the SGSH gene. This enzyme is involved in the lysosomal degradation of heparan sulfate. Mutations in this gene are associated with Sanfilippo syndrome A, one type of the lysosomal storage disease mucopolysaccaridosis III.
The report 'N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H2 2016' outlays comprehensive information on the targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies
It also reviews key players involved in N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 18.104.22.168) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II and Preclinical stages are 5 and 1 respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/284zz8/n
View source version on businesswire.com: http://www.businesswire.com/news/home/20161003006253/en/Business Wire
Last updated on: 03/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.